The University of Chicago Header Logo

Connection

Daniel Arber to Mutation

Back to Details
This is a "connection" page, showing publications Daniel Arber has written about Mutation.
Daniel Arber
Connection Strength
3.701
Mutation
  1. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH. Am J Surg Pathol. 2018 07; 42(7):885-890.
    View in: PubMed
    Score: 0.247
  2. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
    View in: PubMed
    Score: 0.222
  3. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016 09; 29(9):996-1003.
    View in: PubMed
    Score: 0.214
  4. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014 Jul; 99(7):e105-7.
    View in: PubMed
    Score: 0.186
  5. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013 Nov; 27(11):2244-7.
    View in: PubMed
    Score: 0.172
  6. A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. J Mol Diagn. 2009 Jul; 11(4):319-23.
    View in: PubMed
    Score: 0.132
  7. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
    View in: PubMed
    Score: 0.101
  8. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
    View in: PubMed
    Score: 0.101
  9. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
    View in: PubMed
    Score: 0.100
  10. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025 May 07; 15(1):88.
    View in: PubMed
    Score: 0.099
  11. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
    View in: PubMed
    Score: 0.098
  12. TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
    View in: PubMed
    Score: 0.098
  13. The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Adv Anat Pathol. 2025 Jul 01; 32(4):299-306.
    View in: PubMed
    Score: 0.098
  14. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.
    View in: PubMed
    Score: 0.097
  15. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 11 19; 14(1):202.
    View in: PubMed
    Score: 0.096
  16. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
    View in: PubMed
    Score: 0.095
  17. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 08 01; 109(8):2525-2532.
    View in: PubMed
    Score: 0.094
  18. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.093
  19. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
    View in: PubMed
    Score: 0.093
  20. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.093
  21. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 10 03; 160(4):365-393.
    View in: PubMed
    Score: 0.089
  22. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023 Jan; 482(1):27-37.
    View in: PubMed
    Score: 0.083
  23. Erythroleukemia: an Update. Curr Oncol Rep. 2021 04 20; 23(6):69.
    View in: PubMed
    Score: 0.075
  24. How I investigate chronic myelomonocytic leukemia. Int J Lab Hematol. 2020 Apr; 42(2):101-108.
    View in: PubMed
    Score: 0.068
  25. A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. Appl Immunohistochem Mol Morphol. 2019 07; 27(6):416-422.
    View in: PubMed
    Score: 0.066
  26. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017 09; 30(9):1213-1222.
    View in: PubMed
    Score: 0.057
  27. A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol. 2016 10; 29(10):1212-20.
    View in: PubMed
    Score: 0.054
  28. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 08; 29(8):854-64.
    View in: PubMed
    Score: 0.053
  29. The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol. 2015 May; 37 Suppl 1:122-32.
    View in: PubMed
    Score: 0.050
  30. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015 Mar 10; 112(10):E1116-25.
    View in: PubMed
    Score: 0.049
  31. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015; 2015:294-8.
    View in: PubMed
    Score: 0.048
  32. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015 May; 28(5):706-14.
    View in: PubMed
    Score: 0.048
  33. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
    View in: PubMed
    Score: 0.047
  34. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
    View in: PubMed
    Score: 0.026
  35. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
    View in: PubMed
    Score: 0.023
  36. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma. 2023 05; 64(5):972-980.
    View in: PubMed
    Score: 0.021
  37. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
    View in: PubMed
    Score: 0.021
  38. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 04; 98(4):E76-E79.
    View in: PubMed
    Score: 0.021
  39. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
    View in: PubMed
    Score: 0.021
  40. Advances in myelodysplastic/myeloproliferative neoplasms. Virchows Arch. 2023 Jan; 482(1):69-83.
    View in: PubMed
    Score: 0.021
  41. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.021
  42. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 01; 98(1):166-179.
    View in: PubMed
    Score: 0.021
  43. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leuk Res. 2022 12; 123:106965.
    View in: PubMed
    Score: 0.021
  44. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
    View in: PubMed
    Score: 0.020
  45. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 04; 35(4):470-479.
    View in: PubMed
    Score: 0.020
  46. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
    View in: PubMed
    Score: 0.018
  47. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
    View in: PubMed
    Score: 0.015
  48. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
    View in: PubMed
    Score: 0.014
  49. A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. Int J Lab Hematol. 2017 Aug; 39(4):375-383.
    View in: PubMed
    Score: 0.014
  50. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
    View in: PubMed
    Score: 0.011
  51. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012 May; 36(5):744-52.
    View in: PubMed
    Score: 0.010
  52. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012 Aug; 25(8):1128-39.
    View in: PubMed
    Score: 0.010
  53. Histologic and molecular analyses of colonic perineurial-like proliferations in serrated polyps: perineurial-like stromal proliferations are seen in sessile serrated adenomas. Am J Surg Pathol. 2011 Sep; 35(9):1373-80.
    View in: PubMed
    Score: 0.010
  54. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica. 2010 Apr; 95(4):670-3.
    View in: PubMed
    Score: 0.009
  55. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
    View in: PubMed
    Score: 0.008
  56. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005 Oct 15; 106(8):2865-70.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.